Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Coviccine Booster in Adults
NCT05465902Phase 2Withdrawn
- Sponsor
- WestVac Biopharma
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (6 cohorts), sponsored by WestVac Biopharma. Primary endpoints: Incidence of adverse drug reactions and Geometric Mean Titer and Seroconversion Rate of specific neutralizing antibody at Day 14. Planned start Jul 2023; status: withdrawn.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05465902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465902.